The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The analysis, led by Jennifer J Huang, MD, PhD, of Fred Hutchinson Cancer Center of University of Washington in Seattle, was presented at the Fourteenth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
Data from the trial, led by Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, were presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.
Ann LaCasce, MD, MMSc, took an unexpected path to becoming a lymphoma specialist. After someone stole her organic chemistry notebook in college, she traded pre-med for the art world, spending five years working in a contemporary art gallery before returning to medicine
The study evaluated registry data from a heavily pretreated cohort to assess the CAR T-cell therapy’s performance outside of clinical trials. The findings demonstrated high overall response rates and safety profiles consistent with the pivotal TRANSCEND trial.
In this session from the SOHO Insider Community Oncology series, Shakira J. Grant, MBBS, MSCR, founder and CEO of CROSS Global Research and Strategy, discusses how artificial intelligence is shaping pathology workflows and clinical treatment decisions in hematology and oncology.
As part of the SOHO Ambassador Program, the meeting drew approximately two hundred people from across the region and featured top clinicians from France and the United States.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
